Search Results - "Cho, B.C."

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.

Authors: Cho, B.C.

Subjects: Pulmonary Diseases - Radboud University Medical Center.

Index Terms: Article / Letter to editor.

URL: https://hdl.handle.net/2066/315343
https://doi.org/10.1056/NEJMoa2403614

Serial Functional and Genomic Analyses Illuminate Clonal Evolution in Metastatic NSCLC with 12-Year Survival.

Authors: Bakaya, Vikrant S. Schneider, Sabina A. Nguyen, Tracy et al.

Source: Current Oncology; Nov2025, Vol. 32 Issue 11, p646, 7p

Subject Terms: NON-small-cell lung carcinoma, GENOMICS, BRAF genes, EPIDERMAL growth factor receptors, CLONE cells, THERAPEUTICS, METASTASIS, FUNCTIONAL assessment

ERBB2 Mutation Testing in NSCLC: A Pan-European Real-World Evaluation of the Oncomine Precision Assay.

Authors: Alborelli, Ilaria Demes, Melanie Wild, Peter et al.

Source: Journal of Molecular Pathology; Sep2025, Vol. 6 Issue 3, p19, 9p

Subject Terms: NON-small-cell lung carcinoma, HER2 protein, INDIVIDUALIZED medicine, CLINICAL medicine, GENETIC variation, NUCLEOTIDE sequencing, MOLECULAR diagnosis, SENSITIVITY & specificity (Statistics)

Tertiary Lymphoid Structures Are Associated with Favorable Clinical Outcomes and Negatively Correlated with Cancer-Associated Fibroblasts in Esophageal Cancer.

Authors: Kunitomo, Tomoyoshi Noma, Kazuhiro Nishiwaki, Noriyuki et al.

Source: Cancers; Oct2025, Vol. 17 Issue 20, p3351, 16p

Subject Terms: CANCER, ACADEMIC medical centers, MACROPHAGES, DATA analysis, RESEARCH funding, FISHER exact test, ESOPHAGEAL tumors, EVALUATION of medical care, RETROSPECTIVE studies, FLUORESCENT antibody technique, DESCRIPTIVE statistics, MULTIVARIATE analysis, MANN Whitney U Test, FIBROBLASTS, BIOINFORMATICS, IMMUNOHISTOCHEMISTRY, KAPLAN-Meier estimator, LOG-rank test, MONOCYTE lymphocyte ratio, MEDICAL records, ACQUISITION of data, NUTRITIONAL status, STATISTICS, LYMPHOID tissue, PROGRESSION-free survival, DATA analysis software, CONFIDENCE intervals, TUMOR classification, OVERALL survival, B cells, PROPORTIONAL hazards models

Geographic Terms: JAPAN

The Protein Tyrosine Phosphatase 1B Modulates the Activation of Yes-Associated Protein and Sensitizes to Cytotoxic Chemotherapy in Preclinical Models of Cholangiocarcinoma.

Authors: Watkins, Ryan D. Tomlinson, Jennifer L. Buckarma, EeeLN H. et al.

Source: Cells (2073-4409); Oct2025, Vol. 14 Issue 19, p1560, 13p

Subject Terms: PROTEIN-tyrosine phosphatase, CHOLANGIOCARCINOMA, HIPPO signaling pathway, TUMOR growth, CARCINOGENESIS, PHOSPHATASES, CHEMOSENSITIZERS, YAP signaling proteins

Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition.

Authors: Rock, Adam Mambetsariev, Isa Pareek, Siddhika et al.

Source: Current Oncology; Oct2025, Vol. 32 Issue 10, p554, 11p

Subject Terms: EPIDERMAL growth factor receptors, NON-small-cell lung carcinoma, PROTEIN-tyrosine kinase inhibitors, LUNG cancer, TREATMENT failure, CELL transformation, SOMATIC mutation

Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities.

Authors: Catania, Chiara Cascetta, Priscilla Russo, Alessandro et al.

Source: Current Oncology; Oct2025, Vol. 32 Issue 10, p536, 13p

Subject Terms: SMALL cell lung cancer, BIOMARKERS, NEUROENDOCRINE tumors, TREATMENT effectiveness, TRANSCRIPTION factors, THERAPEUTICS, INDIVIDUALIZED medicine, IMMUNOTHERAPY

Dynamics of Telomerase-Based PD-L1 Circulating Tumor Cells as a Longitudinal Biomarker for Treatment Response Prediction in Patients with Non-Small Cell Lung Cancer.

Authors: Sumiyoshi, Issei Togo, Shinsaku Okabe, Takahiro et al.

Source: International Journal of Molecular Sciences; Oct2025, Vol. 26 Issue 19, p9583, 13p

Subject Terms: PROGRAMMED death-ligand 1, NON-small-cell lung carcinoma, BIOMARKERS, BIOPSY, CIRCULATING tumor DNA, INDIVIDUALIZED medicine, TELOMERASE, TREATMENT effectiveness

A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC.

Authors: Burcher, Kimberly Karukonda, Pooja Kelsey, Christopher et al.

Source: Cancers; Jun2025, Vol. 17 Issue 11, p1829, 22p

Subject Terms: THERAPEUTIC use of monoclonal antibodies, MEDICAL quality control, IMMUNOTHERAPY, CLINICAL trials, IMMUNE system, TREATMENT effectiveness, IMMUNE checkpoint inhibitors, CANCER chemotherapy, COMBINED modality therapy, LUNG cancer, TUMOR classification

Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA Testing.

Authors: Muniz, Miguel Tsai, L. Jill Orme, Jacob J. et al.

Source: Cancers; Sep2025, Vol. 17 Issue 18, p3048, 14p

Subject Terms: DNA analysis, GENOMICS, PROSTATE-specific antigen, PROSTATE tumors, RETROSPECTIVE studies, DESCRIPTIVE statistics, BODY fluid examination, TUMOR markers, LONGITUDINAL method, MEDICAL records, ACQUISITION of data, GENETIC mutation, DATA analysis software, GENETIC testing

Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study.

Authors: Oiki, Hana Suda, Kenichi Hamada, Akira et al.

Source: Cells (2073-4409); Sep2025, Vol. 14 Issue 17, p1386, 14p

Subject Terms: AFATINIB, OSIMERTINIB, PROTEIN-tyrosine kinase inhibitors, NON-small-cell lung carcinoma, EPIDERMAL growth factor receptors, TREATMENT effectiveness, IN vitro studies

Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report.

Authors: Steiner, Bradley Edmond, Amanda Camou, Monica et al.

Source: Reports (MDPI AG); Sep2025, Vol. 8 Issue 3, p101, 7p

Subject Terms: OSIMERTINIB, HEPATITIS, LUNG tumors, IMMUNOTHERAPY, SYMPTOMS, ADVERSE health care events, CANCER treatment

Report from the 26th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Hepatocellular and Biliary Tract Cancer, Saskatoon, Saskatchewan, 17–18 October 2024.

Authors: Ravi, Deepti Ahmed, Shahid Anderson, Blaire et al.

Source: Current Oncology; Jul2025, Vol. 32 Issue 7, p398, 18p

Subject Terms: HEPATOCELLULAR carcinoma, BILIARY tract cancer, IMMUNOTHERAPY, MOLECULAR diagnosis, CANCER treatment, INTEGRATED health care delivery, TREATMENT effectiveness, CONFERENCES & conventions

Geographic Terms: WESTERN Canada

Expression Profiles of Co-Inhibitory Receptors in Non-Urothelial Bladder Cancer: Preclinical Evidence for the Next Generation of Immune Checkpoint Inhibitors.

Authors: Rodler, Severin Ledderose, Stephan T. Waidelich, Raphaela et al.

Source: Cancers; Jul2025, Vol. 17 Issue 13, p2210, 10p

Subject Terms: BLADDER tumors, SQUAMOUS cell carcinoma, ADENOCARCINOMA, RESEARCH funding, IMMUNOTHERAPY, SEX distribution, LYMPHOCYTES, TREATMENT effectiveness, AGE distribution, TUMOR markers, QUANTITATIVE research, DESCRIPTIVE statistics, GENE expression, IMMUNE checkpoint inhibitors, GENETIC variation, ANTIGENS, DRUG efficacy, PROGRESSION-free survival

Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study.

Authors: Baser, Mehmet Nuri Demir, Bilgin Serin Ozel, Gamze et al.

Source: Medicina (1010660X); Jul2025, Vol. 61 Issue 7, p1230, 10p

Subject Terms: STATISTICAL significance, TREATMENT duration, OVERALL survival, PROGRESSION-free survival, SURVIVAL rate

Prognostic Significance of Endocrine-Related Adverse Events in Patients with Melanoma, Non-Small Cell Lung Cancer and Urothelial Cancer After Treatment with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

Authors: Kopanos, Stylianos Filippatos, Charalampos Rousakis, Pantelis et al.

Source: Cancers; Nov2025, Vol. 17 Issue 22, p3675, 22p

Subject Terms: BLADDER tumors, MEDICAL information storage & retrieval systems, MELANOMA, HORMONES, IMMUNOTHERAPY, TREATMENT effectiveness, CANCER patients, META-analysis, DESCRIPTIVE statistics, SEVERITY of illness index, IMMUNE checkpoint inhibitors, SYSTEMATIC reviews, ODDS ratio, MEDLINE, MONOCLONAL antibodies, MEDICAL databases, ENDOCRINE diseases, LUNG cancer, DATA analysis software, CONFIDENCE intervals, ONLINE information services, PROGRESSION-free survival, OVERALL survival, BIOMARKERS, EVALUATION, DISEASE risk factors

Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review.

Authors: Loizidis, Sotiris Vogazianos, Paris Kordatou, Zoe et al.

Source: Current Oncology; Nov2025, Vol. 32 Issue 11, p612, 16p

Subject Terms: DOCETAXEL, NON-small-cell lung carcinoma, PROGRESSION-free survival, RETROSPECTIVE studies, IMMUNOTHERAPY, VASCULAR endothelial growth factor antagonists, TREATMENT effectiveness, OVERALL survival

Prognostic Value of Routine Hematological Markers and ECOG Performance in Predicting Overall Survival in Lung Cancer—A Retrospective Cohort Study and Literature Review.

Authors: Ion-Andrei, Denisa-Gabriela Gache, Alexandra-Cristiana Mocanu, Elena et al.

Source: Journal of Clinical Medicine; Nov2025, Vol. 14 Issue 21, p7603, 17p

Subject Terms: LUNG cancer, OVERALL survival, BIOMARKERS, FUNCTIONAL status, SURVIVAL analysis (Biometry), PROGNOSTIC tests, COHORT analysis

Revisiting p53 Immunohistochemical Staining and Its Prognostic Implications in Advanced EGFR-Mutated Lung Adenocarcinoma.

Authors: Kuan, Feng-Che Chang, Shun-Fu Yang, Yao-Ren et al.

Source: Cancers; Nov2025, Vol. 17 Issue 21, p3577, 13p

Subject Terms: ANTINEOPLASTIC agents, ADENOCARCINOMA, RESEARCH funding, RECEIVER operating characteristic curves, DESCRIPTIVE statistics, RETROSPECTIVE studies, TUMOR suppressor genes, IMMUNOHISTOCHEMISTRY, LONGITUDINAL method, KAPLAN-Meier estimator, LUNG tumors, STATISTICS, GENETIC mutation, SURVIVAL analysis (Biometry), DATA analysis software, PROGRESSION-free survival, BIOMARKERS, PROPORTIONAL hazards models, OVERALL survival

Prevalence of Histological Transformation in First-Line Osimertinib Non-Small Cell Lung Cancers: Case Series and Literature Review.

Authors: Sparavelli, Rebecca Bruno, Rossella Celi, Alessandra et al.

Source: International Journal of Molecular Sciences; Nov2025, Vol. 26 Issue 21, p10462, 16p

Subject Terms: OSIMERTINIB, NON-small-cell lung carcinoma, LUNG tumors, EPIDERMAL growth factor receptors, CELL transformation, BIOPSY, P53 protein